Follow-up of children born of bromocriptine-treated mothers.
A survey carried out in France at the beginning of 1984 concerning development of children born of mothers treated with bromocriptine (BC) during part or all of the pregnancy showed the absence of any adverse effects of BC in 64 children born from 53 mothers. In 60 cases, BC was prescribed (2.5-7.5 mg/day) for hyperprolactinemia; 23 mothers were treated with BC for 4 weeks or less, and 23 others for 30 weeks or more. After a follow-up of between 6 months and 9 years, all children are normal. Psychological development in the 23 children born to mothers treated with BC during more than 30 weeks of pregnancy actually appears more precocious, with excellent scholastic performance in the oldest.
D000236:Adenoma / Q000188:drug therapy*; D001724:Birth Weight; D001971:Bromocriptine / Q000627:therapeutic use*; D002657:Child Development / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011247:Pregnancy / Q000187:drug effects*; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D013997:Time Factors
D001971:Bromocriptine